Back to all news
Macro Finance

Lilly Buying Spree Surpasses $32B

Bloomberg Markets·November 18, 2026·1 min read

Eli Lilly agreed to buy closely held Calytrix Bio in a deal that could be worth up to $1.5 billion, the latest in the drugmaker's $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. The acquisition was reported by Bloomberg's Madison Muller on "Bloomberg Deals."

Read at Bloomberg Markets
Daily crypto arcade

Read the news, then play it.

Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.

Open ChainshortsGet it on the Solana dApp Store